Interstitial lung diseases (ILDs) represent a diverse group of more than 200 lung disorders characterized by inflammation and fibrosis of the lung interstitium. This article aims to provide healthcare professionals with a comprehensive understanding of ILDs, their diagnosis, and treatment options.
ILDs can be idiopathic or secondary to systemic diseases, occupational and environmental exposures, or drug toxicity. The pathogenesis typically involves damage to the lung interstitium, leading to an aberrant repair response, inflammation, fibrosis, and ultimately, loss of lung function.
Patients with ILDs often present with non-specific symptoms such as dyspnea, cough, and fatigue. High-resolution computed tomography (HRCT) is the cornerstone of ILD diagnosis. Pulmonary function tests, bronchoalveolar lavage, and lung biopsy may also be used for diagnosis and to assess disease severity.
Management strategies for ILDs are multifaceted and depend on the underlying cause. In idiopathic cases, treatment is largely supportive, including supplemental oxygen and pulmonary rehabilitation. Pharmacological therapies, such as corticosteroids and immunosuppressants, are used in cases of inflammatory ILDs. Antifibrotic agents are increasingly used in managing fibrotic ILDs. Lung transplantation remains a last resort for patients with advanced disease.
Given the complexity of ILDs, a multidisciplinary approach is essential for optimal patient management. This approach includes pulmonologists, radiologists, pathologists, rheumatologists, and patient support groups. This collaborative approach ensures comprehensive patient care and improves outcomes.
Interstitial lung diseases are complex disorders requiring a thorough understanding for effective management. As healthcare professionals, staying updated on the latest diagnostic and therapeutic advances is crucial to provide the best possible care for patients with ILDs.
1.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
2.
Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.
3.
Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer
4.
CAR T cells improve patients' quality of life: a study
5.
Preoperative Embolization Linked to Relapse-Free Survival in Meningioma
1.
The Digital Revolution in Oncology - How Software, AI, and Data are Reshaping Cancer Care by 2025
2.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
3.
Bone Marrow Niche Remodeling in Hematologic Dysfunction
4.
Public Health Strategies for Expanding Early Support Systems in Blood Disorders
5.
Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation